Selected article for: "ARDS respiratory distress syndrome and hyaline membrane"

Author: Yin Wang; Weiwei Jiang; Qi He; Cheng Wang; Baoju Wang; Pan Zhou; Nianguo Dong; Qiaoxia Tong
Title: Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China
  • Document date: 2020_3_12
  • ID: 23mp5961_1
    Snippet: Corona Virus Disease 2019 (COVID- 19) was first reported in late December 2019, originating in Wuhan, China and then transmitted in Hubei Province, throughout China and even other countries [1, 2] . This ongoing outbreak has already been declared by World Health Organization(WHO) as a Public Health Emergency of International Concern (PHEIC). As of February 28, there are 78,824 confirmed cases, 7,952 severe cases and 2,788 confirmed deaths across .....
    Document: Corona Virus Disease 2019 (COVID- 19) was first reported in late December 2019, originating in Wuhan, China and then transmitted in Hubei Province, throughout China and even other countries [1, 2] . This ongoing outbreak has already been declared by World Health Organization(WHO) as a Public Health Emergency of International Concern (PHEIC). As of February 28, there are 78,824 confirmed cases, 7,952 severe cases and 2,788 confirmed deaths across China [3] . COVID-19 is a beta-coronavirus, presenting as viral pneumonia with high infectiousness through respiratory droplets or direct contact and appears to have greater infectivity and a lower-case fatality rate when compared to severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome(MERS) [4, 5] . Moreover, the pathological features of COVID-19 pneumonia greatly resemble those seen in SARS and MERS, and show diffuse alveolar damage with cellular fibromyxoid exudates, desquamation of pneumocytes and hyaline membrane formation, indicating acute respiratory distress syndrome(ARDS) [6] .

    Search related documents:
    Co phrase search for related documents